UK Cannabis Industry Watch: Lyphe Group Restructures Volte Face report The UK’s largest medical cannabis company has announced a new capital raise and the completion of an internal restructure. The next chapter of our growth is set to bring many exciting and accretive opportunities.” As the largest medical cannabis company in the UK, this announcement is significant for the industry and for patients. The company has completed a top-down restructuring to various teams across the business to refocus on a core UK market, as well as strategically replicate their model in Australia. Lyphe Group launched in Australia a few months ago and will continue to operate there, where the board recognises the potential for significant bottom-line contribution.
Volte Face report
The UK’s largest medical cannabis company has announced a new capital raise and the completion of an internal restructure.
This new raise will support Lyphe Group to become cash flow positive later this year. This alongside the consolidation of its supply chain and operating cost base, which will result in over £4m annualised savings this year. The company has completed a top-down restructuring to various teams across the business to refocus on a core UK market, as well as strategically replicate their model in Australia.
Lyphe Group has appointed a...
Read the full article @ Cannabis Law Report